Roivant Sciences (ROIV) News Today $11.15 +0.26 (+2.39%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Roivant Sciences Sees Unusually High Options Volume (NASDAQ:ROIV)Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) saw some unusual options trading on Friday. Investors purchased 32,948 call options on the company. This is an increase of approximately 1,371% compared to the typical daily volume of 2,240 call options.January 17 at 4:54 PM | marketbeat.comRoivant Sciences augmente sa participation dans Immunovant avec un achat de 336,9 millions de dollarsJanuary 16, 2025 | fr.investing.comRoivant Sciences buys Immunovant Inc. shares and repurchases its own stock for $336.9 million eachJanuary 16, 2025 | finance.yahoo.comRoivant Sciences Ltd. (NASDAQ:ROIV) Director Acquires $336,900,200.00 in StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) Director Sciences Ltd. Roivant purchased 16,845,010 shares of the firm's stock in a transaction that occurred on Monday, January 13th. The stock was bought at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the purchase, the director now owns 96,650,341 shares in the company, valued at $1,933,006,820. This represents a 21.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.January 15, 2025 | marketbeat.comIs Roivant Sciences (ROIV) the Best Medical Stock to Buy Under $20?January 12, 2025 | insidermonkey.comNordea Investment Management AB Has $3.31 Million Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)Nordea Investment Management AB lifted its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 22.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 282,834 shares of the company's sJanuary 11, 2025 | marketbeat.comWhy Ramaswamy Says America Needs a Cultural Shift Towards Excellence for the Sake of US StudentsJanuary 7, 2025 | msn.comWhy Ramaswamy Says America Needs a Cultural Shift Toward Excellence for the Sake of US StudentsJanuary 6, 2025 | msn.comRoivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven haJanuary 3, 2025 | marketbeat.comEric Venker Sells 177,704 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) StockJanuary 1, 2025 | insidertrades.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $2,050,704.16 in StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 177,704 shares of the stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $11.54, for a total transaction of $2,050,704.16. Following the completion of the transaction, the chief operating officer now owns 740,976 shares in the company, valued at $8,550,863.04. This trade represents a 19.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.December 31, 2024 | marketbeat.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 176,900 Shares of StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 176,900 shares of the firm's stock in a transaction on Friday, December 27th. The shares were sold at an average price of $11.82, for a total value of $2,090,958.00. Following the completion of the sale, the chief operating officer now directly owns 668,680 shares of the company's stock, valued at approximately $7,903,797.60. This trade represents a 20.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.December 31, 2024 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Principal Financial Group Inc.Principal Financial Group Inc. lowered its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 12.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,009,758 shares of the company's sDecember 30, 2024 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,149,000.00 in StockDecember 27, 2024 | insidertrades.comLe directeur des investissements de Roivant Sciences, Mayukh Sukhatme, vend pour 10,6 millions de dollars d'actionsDecember 27, 2024 | fr.investing.comLe président de Roivant Sciences, Eric Venker, vend pour 1,15 million de dollars d'actionsDecember 27, 2024 | fr.investing.comEric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 100,000 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $11.49, for a total transaction of $1,149,000.00. Following the completion of the sale, the chief operating officer now directly owns 595,580 shares in the company, valued at approximately $6,843,214.20. This trade represents a 14.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.December 26, 2024 | marketbeat.comMayukh Sukhatme Sells 185,946 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CIO Mayukh Sukhatme sold 185,946 shares of the business's stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $12.00, for a total value of $2,231,352.00. Following the transaction, the executive now owns 18,836,547 shares of the company's stock, valued at approximately $226,038,564. The trade was a 0.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.December 26, 2024 | marketbeat.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CIO Sells 689,495 Shares of StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CIO Mayukh Sukhatme sold 689,495 shares of the firm's stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $12.01, for a total value of $8,280,834.95. Following the completion of the transaction, the executive now owns 18,836,547 shares of the company's stock, valued at $226,226,929.47. This trade represents a 3.53 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.December 26, 2024 | marketbeat.comBarclays PLC Purchases 75,609 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)Barclays PLC grew its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 19.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 459,521 shares of the company's stock after purchasing an additional 75,December 21, 2024 | marketbeat.comMayukh Sukhatme Sells 412,584 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CIO Mayukh Sukhatme sold 412,584 shares of the firm's stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $12.05, for a total value of $4,971,637.20. Following the completion of the transaction, the executive now owns 18,836,547 shares in the company, valued at approximately $226,980,391.35. This trade represents a 2.14 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.December 20, 2024 | marketbeat.comGeode Capital Management LLC Acquires 1,460,205 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)Geode Capital Management LLC grew its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 23.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 7,745,104 shares of the company's stock after acquiring an additional 1,460,205 shares duriDecember 20, 2024 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Purchased by Retirement Systems of AlabamaRetirement Systems of Alabama raised its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 26.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 530,022 shares of the company's stock after acquiringDecember 19, 2024 | marketbeat.comRoivant Sciences (ROIV) Receives a Buy from Leerink PartnersDecember 18, 2024 | markets.businessinsider.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Acquired by State Street CorpState Street Corp lifted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 6.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 19,561,249 shares of the company's stock after purchasing an additional 1,118,561 shares dDecember 12, 2024 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to tDecember 9, 2024 | marketbeat.comRoivant Sciences Stock Forecast: Bullish Trends and Key Performance MetricsDecember 6, 2024 | theglobeandmail.comBrokers Issue Forecasts for ROIV Q3 EarningsRoivant Sciences Ltd. (NASDAQ:ROIV - Free Report) - Equities research analysts at Leerink Partnrs issued their Q3 2025 earnings estimates for shares of Roivant Sciences in a report issued on Tuesday, December 3rd. Leerink Partnrs analyst D. Risinger anticipates that the company will post earningsDecember 6, 2024 | marketbeat.comEdgestream Partners L.P. Purchases Shares of 48,226 Roivant Sciences Ltd. (NASDAQ:ROIV)Edgestream Partners L.P. acquired a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 48,226 shares of the company's stock, valued at approximately $557,000. Several otherDecember 6, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $26.63 Million Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 49.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,307,December 5, 2024 | marketbeat.comMetLife Investment Management LLC Has $2.60 Million Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)MetLife Investment Management LLC boosted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 26.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 225,320 shares of the company's stock after purchasing aDecember 5, 2024 | marketbeat.comRoivant Sciences Unit Kinevant Sciences' Lung Disease Drug Fails in Mid-Stage StudyDecember 4, 2024 | marketwatch.comRoivant to stop lung disease drug development after trial failureDecember 4, 2024 | msn.comRoivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary SarcoidosisDecember 4, 2024 | markets.businessinsider.comRoivant Sciences: A Biotech Growth Play With Major AmbitionsDecember 4, 2024 | seekingalpha.comMaven Securities LTD Invests $4.62 Million in Roivant Sciences Ltd. (NASDAQ:ROIV)Maven Securities LTD acquired a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 400,000 shares of the company's stock, valued at approximatelDecember 4, 2024 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Melqart Asset Management UK LtdMelqart Asset Management UK Ltd trimmed its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 41.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 742,070 shares of the company's stockDecember 4, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Buys 646,627 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)Charles Schwab Investment Management Inc. grew its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 30.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,767,412 shares of the company's stock after acquiring an addDecember 4, 2024 | marketbeat.comRoivant Sciences Ends Namilumab Study Due to InefficacyDecember 3, 2024 | tipranks.comRoivant's lung disease drug fails mid-stage trialDecember 3, 2024 | reuters.com214,000 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Acquired by Erste Asset Management GmbHErste Asset Management GmbH bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 214,000 shares of the company's stock,December 3, 2024 | marketbeat.comTOMS Capital Investment Management LP Acquires Shares of 4,015,000 Roivant Sciences Ltd. (NASDAQ:ROIV)TOMS Capital Investment Management LP bought a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 4,015,000 shares of the company's stDecember 2, 2024 | marketbeat.comThrivent Financial for Lutherans Sells 62,228 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)Thrivent Financial for Lutherans lessened its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 33.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 123,823 shares of the company's stock after selling 62,228 shares duringDecember 1, 2024 | marketbeat.comFmr LLC Has $567.13 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV)Fmr LLC raised its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 5.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 49,145,056 shares of the company's stock after acquiring an additioNovember 29, 2024 | marketbeat.comRoivant Sciences Ltd Stock Forecast: AI Predicts 44% Upside PotentialNovember 28, 2024 | theglobeandmail.comRoivant Sciences Ltd. (NASDAQ:ROIV) is Rubric Capital Management LP's 4th Largest PositionRubric Capital Management LP lessened its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 2.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 22,400,000 shares of the company's stock after sellinNovember 27, 2024 | marketbeat.comLoomis Sayles & Co. L P Purchases 458,601 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)Loomis Sayles & Co. L P grew its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 13.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,912,205 shares of the company's stock after buying an addNovember 26, 2024 | marketbeat.comVivek Ramaswamy’s crusade to change FDA could boost biotech, and himselfNovember 25, 2024 | msn.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 SharesNovember 23, 2024 | insidertrades.comThompson Siegel & Walmsley LLC Takes $5.93 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV)Thompson Siegel & Walmsley LLC acquired a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 513,632 shares of the company's stock, valued at approximately $5,927,November 22, 2024 | marketbeat.com Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Email Address ROIV Media Mentions By Week ROIV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ROIV News Sentiment▼1.050.44▲Average Medical News Sentiment ROIV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ROIV Articles This Week▼65▲ROIV Articles Average Week Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BNTX News Today TEVA News Today BGNE News Today GMAB News Today VTRS News Today ITCI News Today SMMT News Today MRNA News Today RDY News Today CTLT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ROIV) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
